Observational study on characteristics and outcomes of patients with surgically removed lung cancers
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
This study looks at patients in China who have had lung cancer surgery to see how their treatment and outcomes vary and what factors might affect their survival.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06255197 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with surgically resected lung cancers in China, utilizing real-world data to analyze treatment patterns and outcomes. It aims to describe patient characteristics, identify trends in treatment, and explore factors associated with overall survival. By leveraging advanced data processing algorithms and ensuring data quality, the study seeks to address emerging clinical questions related to lung cancer treatment. The findings could provide valuable insights into the evolving landscape of lung cancer management.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 who have undergone surgical resection for lung malignancies.
Not a fit: Patients with low-quality data or incomplete medical records may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of treatment patterns and improve outcomes for lung cancer patients.
How similar studies have performed: Other studies utilizing real-world data in lung cancer have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age above 18. * Have received surgical resection for lung malignancies. Exclusion Criteria: * Participants whose data are of low quality, poor completeness or poor internal linkage.
Where this trial is running
Beijing, Beijing Municipality
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Jie He, MD-PhD — National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS and PUMC
- Study coordinator: Fengwei Tan, MD-PhD
- Email: tanfengwei@126.com
- Phone: +8601087787792
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.